Investors have had a wild ride in 2025. With the stock market down by double-digits and what looked like a bear market in the making, the S&P 500 and NASDAQ-100 have recovered all of their losses and are now positive year-to-date. Investors are trying to look beyond the trade deal being temporary as a template for what to expect from other countries negotiating their own trade deals. Now for the big question — what are investors supposed to do now if they missed this recovery rally?
Oggonomics tracks the daily flow of Wall Street analyst research reports in an effort to find new ideas and hidden gems that might have otherwise been overlooked. The trend for the last 45 to 60 days has been for brokerage firms to maintain their analyst ratings while slashing price target drastically lower to reflect lower share price expectations and a much slower economy.
While Wall Street has been slow to issue formal rating downgrades with those price target cuts, finding formal analyst upgrades and seeing significant price target hikes has also been rare. Oggonomics is tracking 7 analyst upgrades and/or price target hikes that standout from the 100-plus analyst calls issued on Wednesday, May 14, 2025 with Buy/Outperform ratings and with significant implied upside to their price targets.
Investors need to keep in mind that no single analyst report should ever be the sole basis to buy or sell a stock. Analysts can get their thesis wrong and fundamentals can change in the blink of an eye. Please read the disclaimer at the end of this report because no analyst report ever comes with any guarantees.
Chimera Investment Corporation (NYSE: CIM) was raised to Buy from Neutral and its price target was raised to $15 from $11.50 (versus $13.03 close) at UBS. Chimera’s 52-week range is $9.85 to $16.89 and the MBS-REIT screens as an 11% dividend yield.
Dutch Bros Inc. (NYSE: BROS) was started as Outperform in new coverage with a $83 price target (versus $70.23 prior close) at RBC Capital Markets. Dutch Bros is up about 20% in the last month and it is up about 34% since the start of 2025.
Franklin Resources Inc. (NYSE: BEN) was raised to Buy from Hold and its price target was raised to $27 from $21.50 (versus $21.58 close) at TD Cowen. Franklin Resources has a 52-week range of $16.25 to $24.86. While Franklin has had its share of troubles for shareholders, the stock is currently up almost 7% YTD and it has rallied about 20% over the last month.
KKR & Co. Inc. (NYSE: KKR) was raised to Overweight from Equal-Weight and its price target was raised to $150 from $120 at Morgan Stanley. TD Cowen also reiterated its Buy rating and raised its target to $148 from $136. KKR closed at $126.90 ahead of the calls.
ALSO READ: HOW INVESTING IN STORAGE UNITS CAN PAY OFF BIG-TIME!
Omnicell, Inc. (NASDAQ: OMCL) was raised to Overweight from Equal Weight and its price target was raised to $35 from $31 (versus $28.00 close) at Wells Fargo. Omnicell’s 52-week range is $22.66 to $55.75 and its stock is down 34% YTD.
ON Semiconductor Corporation (NASDAQ: ON) saw several price target hikes with ratings reiterated: Baird (Outperform) target to $70 from $63; KeyCorp (Overweight) target to $68 from $60; and Needham (Buy) target to $62 from $55. ON Semi closed at $45.77 prior to the calls with a $52-week trading range of $31.04 to $80.08.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was raised to Buy from Neutral and its price target was raised to $700 from $600 (versus $574.16 prior close) at Citigroup. Regeneron has a 52-week range of $520.50 to $1,211.20. This stock is down about 18% YTD and down 40% from a year ago.
If you missed out on Tuesday’s top analyst upgrades for big upside, they included Caterpillar, First Solar, Payoneer, Peloton, Stanley Black & Decker, Super Micro, Terex and others.
Please note that all analyst ratings and the price targets mentioned in this report were issued by each firm named above. Those are their ratings and targets and they may differ greatly from firm to firm. Oggonomics does not issue any formal ratings and price targets of its own on these stocks. Investing involves significant risks, and no analyst reports, even those with very strong conviction, ever come with any guarantees of profits. These research reports also never issue any money-back guarantees in case you lose money.
